Title:
ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
Document Type and Number:
Japanese Patent JP4238728
Kind Code:
B2
Abstract:
A therapeutic agent for prostate cancer and malignant lymphoma containing FK228 or a salt thereof as an active ingredient, and a method for evaluating an antitumor effect of a histone deacetylase inhibitor which includes at least a step of treating a test cell with a histone deacetylase inhibitor, a step of measuring change in the expression amount of a specific gene in the test cell before and, after the treatment with the inhibitor, comparing the both expression amounts.
Inventors:
Yuka Sasakawa
Naoe Yoshinori
Naoe Yoshinori
Application Number:
JP2003520768A
Publication Date:
March 18, 2009
Filing Date:
August 20, 2002
Export Citation:
Assignee:
Astellas Pharma Inc.
International Classes:
A61K38/00; A61K38/12; A61K38/15; A61P13/08; A61P35/00; A61P43/00; C12Q1/34; C12Q1/68; G01N33/50; G01N33/574
Domestic Patent References:
| JP11335375A |
Foreign References:
| WO2001018171A1 | ||||
| WO1998040080A1 |
Other References:
John C. Byrd,Blood,1999年,Vol.94, No.4,Pages 1401-1408
Hiroshi Kosugi,Jpn. J, Cancer Res.,2001年 5月,Vol.92,Pages 529-536
Hidenori Nakajima,Experimental cell research,1998年,Vol.241,Pages 126-133
Hiroshi Kosugi,Jpn. J, Cancer Res.,2001年 5月,Vol.92,Pages 529-536
Hidenori Nakajima,Experimental cell research,1998年,Vol.241,Pages 126-133
Attorney, Agent or Firm:
Takashima Ichi